

ALMA VEIL LAUNCHES IN CANADA

Multi-technology platform brings 532 nm, 1064 nm and MicroPulse™ capabilities together in a single handpiece

TORONTO, ONTARIO , CANADA, September 10, 2026 /EINPresswire.com/ -- Alma North America,

“

Alma Veil in Canada reflects our continued commitment to providing practices with thoughtfully designed technologies that support versatility and individualized patient care”

*Spencer Detter, President
Alma North America*

a global leader in energy-based medical and aesthetic solutions, today announced the Canadian launch of Alma Veil, a multi-technology platform now available to medical aesthetic professionals across Canada. Designed for medical aesthetic professionals, Alma Veil brings three complementary technologies into one handpiece to support individualized treatment approaches across vascular, pigmented and skin quality concerns.

Alma Veil combines 532 nm and 1064 nm wavelengths with MicroPulse™ technology. The 532 nm wavelength is designed for more superficial targets, while 1064 nm

reaches deeper vascular structures. MicroPulse technology expands the platform’s capabilities for skin quality treatments with minimal downtime. Together, the three modalities allow providers to select the technology best suited to the clinical concern and treatment plan. “Alma Veil is an important addition for providers across Canada,” said Cory Murrell, General Manager, Canada. “By integrating three complementary technologies in one handpiece—with precise energy delivery, contact cooling and no required consumables—the platform gives practices a versatile way to address a broad range of patient needs.”

Alma Veil features:

- A 532 nm wavelength for superficial vascular lesions
- A 1064 nm wavelength for deeper vascular lesions
- MicroPulse technology for addressing skin quality concerns with minimal downtime
- A single handpiece integrating all three technologies
- Contact cooling for patient comfort and safety
- An all-inclusive workstation with no required cryogenes, dyes or other treatment consumables
- Purpose-built platform stability and consistent energy delivery
- DermaCore™ Delivery, engineered to modulate pulse sequence and support simultaneous targeting of larger and smaller vascular structures in each pulse

Veil-specific clinical evidence includes a multicenter retrospective case series evaluating 13 adults treated across three dermatology practices for vascular-predominant rosacea and facial

telangiectasia. At follow-up, treating physicians reported a mean Global Aesthetic Improvement Scale score of 4.23 out of 5, while mean patient satisfaction was 4.31 out of 5. Independent blinded reviewers found moderate-to-high photographic improvement. Mean reported pain was 2.54 out of 10, and no adverse events were reported. The authors concluded that a depth-directed 532/1064 nm workflow produced clinically meaningful clearance with high patient satisfaction and low discomfort in routine practice.¹

The Canadian launch of Alma Veil expands Alma North America's portfolio with a configurable platform designed to help dermatologists, plastic surgeons, physicians and other medical aesthetic professionals tailor treatments to individual patient needs. "The launch of Alma Veil in Canada reflects our continued commitment to providing practices with thoughtfully designed technologies that support versatility and individualized patient care," said Spencer Detter, President of Alma North America. "We are proud to expand access to a platform that brings multiple capabilities together in one streamlined system." Alma Veil officially launches in Canada on August 24, 2026. Providers interested in learning more can visit www.almainc.com or contact their local Alma representative.

CLINICAL SOURCE

1. Hsu JTS, Dy L, Desai S. Dual-Wavelength Laser Therapy for Vascular-Predominant Rosacea and Facial Telangiectasia: A Multicenter Retrospective Case Series. Alma Blueprint, Edition 1. 2026. Alma data on file.

ABOUT ALMA

Alma is a global innovator of laser, light-based, radiofrequency, plasma and ultrasound solutions for the aesthetic and surgical markets. With one of the industry's most comprehensive portfolios of energy-based technologies, Alma develops solutions designed to support practitioners, elevate the patient experience and move the aesthetic industry forward.

For more information, visit <https://almainc.ca/>

Shana Partl
ALMA LASERS
jec@blupr.com

This press release can be viewed online at: <https://www.einpresswire.com/article/941219399>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.